mRNA Expression Profiles of MethylatedAPAF-1andDAPK-1Tumor Suppressor Genes Uncover Clear Cell Renal Cell Carcinomas With Aggressive Phenotype
Authors:
- 1 December 2007
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 178 (6) , 2655-2659
Abstract
We determined the relation between promoter methylation and mRNA expression of the p53 target genes APAF-1 and DAPK-1 in 55 consecutive tumor and corresponding normal tissue samples. Tissue was taken from nonmetastatic clear cell renal cell carcinoma at a median followup of 75 months. Quantitative methylation specific real-time polymerase chain reaction and quantitative real-time reverse transcriptase-polymerase chain reaction were used. The mRNA expression levels of APAF-1 and DAPK-1 were significantly higher in tumor vs nontumor tissue from the same kidney (p = 0.003 and 0.0001, respectively). Expression levels of the 2 genes did not correlate with tumor stage but they were significantly lower in high grade (G3) tumors (p = 0.018 and 0.05, respectively). In patients with positive lymph node staging mRNA expression of APAF-1 and DAPK-1 was significantly lower. On matched pair analysis of tumor tissue the methylation level of the APAF-1 gene correlated inversely with the mRNA expression level (p = 0.02). In tumor and normal kidney tissue from patients with lesions 4 cm or greater mRNA expression levels of DAPK-1 were significantly lower in those who later had metastatic disease (p = 0.04 and 0.02, respectively). These data demonstrate decreased tumor suppressor gene expression in more aggressive subtypes of clear cell renal cell carcinoma. The lower mRNA level of the DAPK-1 gene in tumor and normal tissue from patients with an unfavorable clinical outcome suggests the organ specific loss of tumor suppressor gene expression, predisposing to metastatic tumor disease and shorter overall survival.Keywords
This publication has 19 references indexed in Scilit:
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancerBritish Journal of Cancer, 2006
- Promoter Hypermethylation Profile of Kidney Cancer with New Proapoptotic p53 Target Genes and Clinical ImplicationsClinical Cancer Research, 2006
- Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Renal Cell Carcinoma With Nodal Metastases in the Absence of Distant Metastatic Disease (Clinical Stage TxN1-2M0): The Impact of Aggressive Surgical Resection on Patient OutcomeJournal of Urology, 2006
- Expression of death-associated protein kinase during tumour progression of human renal cell carcinomas: Hypermethylation-independent mechanisms of inactivationEuropean Journal of Cancer, 2006
- Promoter Hypermethylation Profile of Kidney CancerClinical Cancer Research, 2004
- Reassessment of the 1997 TNM classification system for renal cell carcinomaCancer, 2003
- Role of DNA methylation in the suppression of Apaf-1 protein in human leukaemiaOncogene, 2003
- Mutations of the VHL tumour suppressor gene in renal carcinomaNature Genetics, 1994